Showing results (81-90 of 98) with videos related to
Sort By:
Pageof 10
Molecular Cancer Therapeutics|March 16, 2021
Calicheamicin Antibody-Drug Conjugates with Improved PropertiesBreanna S Vollmar, Chris Frantz, Melissa M Schutten, et al.Nature Chemistry|November 23, 2016
Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugatesLeanna R Staben, Stefan G Koenig, Sophie M Lehar, et al.Bioconjugate Chemistry|February 27, 2018
Modulating Antibody-Drug Conjugate Payload Metabolism by Conjugation Site and Linker ModificationDian Su, Katherine R Kozak, Jack Sadowsky, et al.Bioconjugate Chemistry|June 22, 2017
Development of Efficient Chemistry to Generate Site-Specific Disulfide-Linked Protein- and Peptide-Payload Conjugates: Application to THIOMAB Antibody-Drug ConjugatesJack D Sadowsky, Thomas H Pillow, Jinhua Chen, et al.Journal of Medicinal Chemistry|September 6, 2014
Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineeringThomas H Pillow, Janet Tien, Kathryn L Parsons-Reponte, et al.Chemistry (Weinheim an Der Bergstrasse, Germany)|March 2, 2018
Conjugation of Indoles to Antibodies through a Novel Self-Immolating LinkerPeter S Dragovich, Robert A Blake, Chunjiao Chen, et al.Journal of Medicinal Chemistry|December 12, 2017
Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease SpecificityBinQing Wei, Janet Gunzner-Toste, Hui Yao, et al.Molecular Cancer Therapeutics|February 23, 2017
Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide LinkersThomas H Pillow, Melissa Schutten, Shang-Fan Yu, et al.Bioanalysis|November 19, 2016
2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 2 - Hybrid LBA/LCMS and input from regulatory agencies)An Song, Anita Lee, Fabio Garofolo, et al.Bioorganic & Medicinal Chemistry Letters|March 19, 2011
Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitorsJohn L Buchanan, John R Newcomb, David P Carney, et al.Pageof 10